Board Member
AN2 Therapeutics, Inc. (ANTX)Equibles does not estimate personal net worth.
Eric Easom is recorded as Board Member and CEO at AN2 Therapeutics, Inc. (ANTX). The newest filing on record that lists Eric Easom as Board Member and CEO at AN2 Therapeutics, Inc. (ANTX) is dated April 22, 2026. The proxy statement of AN2 Therapeutics, Inc. reports total compensation of $1,382,985 for Eric Easom in fiscal 2025, including a base salary of $603,750. Disclosed compensation is on record for 5 fiscal years. Eric Easom has spoken on 1 investor event across 1 company, most recently for AN2 Therapeutics, Inc. on June 4, 2026. AN2 Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at AN2 Therapeutics, Inc. includes Lucy Day (CFO and Chief Accounting Officer), Josh Eizen (COO), Joshua Eizen (COO and General Counsel) and 7 others.
“I'll be talking about things that have forward-looking statements.”
Start not stated–present
Last confirmed April 22, 2026
Start not stated–present
Last confirmed April 22, 2026
Biotechnology · Healthcare
Board Member, CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | AN2 Therapeutics, Inc. (ANTX) | President, Chief Executive Officer and Board Chair | $603,750 | $1,382,985 |
| 2024 | AN2 Therapeutics, Inc. (ANTX) | President, Chief Executive Officer and Board Chair | $603,750 | $1,666,117 |
| 2023 | AN2 Therapeutics, Inc. (ANTX) | President, Chief Executive Officer and Board Chair | $575,000 | $3,342,848 |
| 2022 | AN2 Therapeutics, Inc. (ANTX) | President and Chief Executive Officer | $481,185 | $3,465,533 |
| 2021 | AN2 Therapeutics, Inc. (ANTX) | President, Chief Executive Officer and Director | $377,300 | $1,718,989 |
